Remote operation software developer Guident (GDNT.US) applies for U.S. listing, plans to raise $17 million.
Guident submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission on Thursday, with plans to raise up to $17 million.
Guident (GDNT.US), which develops remote monitoring and remote control software for autonomous vehicles and Siasun Robot&Automation, submitted its initial public offering (IPO) application to the US Securities and Exchange Commission on Thursday, planning to raise up to $17 million. The pricing range for the IPO has not yet been disclosed.
Guident primarily provides remote monitoring and control services and solutions for autonomous vehicles (AV) and Siasun Robot&Automation. Its remote monitoring and control center platform utilizes internally developed artificial intelligence software and large language models developed by third parties to assess risks and allow system operators to take control measures when necessary. In addition, Guident also offers autonomous monitoring and inspection capabilities for Siasun Robot&Automation with the same monitoring and control functions.
The company, headquartered in Boca Raton, Florida, was founded in 2020 and had sales of $74,000 in the 12 months ending June 30, 2025. Guident plans to list on the Nasdaq under the ticker symbol GDNT. The company secretly submitted the IPO application on May 9, 2025, with Prime Number Capital and Dominari Securities serving as joint bookrunners for the transaction.
Related Articles

On September 19th, FIH purchased 43,000 shares for 724,400 Hong Kong dollars.

FOUNDER HOLD (00418) spent HK$156,000 on September 19 to repurchase 200,000 shares.

: Maintains "buy" rating on HORIZONROBOT-W (09660) with a target price of HK$12.44.
On September 19th, FIH purchased 43,000 shares for 724,400 Hong Kong dollars.

FOUNDER HOLD (00418) spent HK$156,000 on September 19 to repurchase 200,000 shares.

: Maintains "buy" rating on HORIZONROBOT-W (09660) with a target price of HK$12.44.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025